Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272996 | 0.95 | SLC2A1 (0.56) | SLC2A1KCNH2SLC22A12 | |
| SCHEMBL4273002 | 0.95 | SLC2A1 (0.56) | SLC2A1KCNH2SLC22A12 | |
| SCHEMBL4272989 | 0.95 | SLC2A1 (0.56) | SLC2A1KCNH2SLC22A12 | |
| SCHEMBL5725729 | 0.85 | SLC2A1 (0.53) | SLC2A1KCNH2KDM4E | |
| SCHEMBL27577193 | 0.82 | SLC2A1 (0.53) | SLC2A1KCNH2KDM4E | |
| SCHEMBL4277320 | 0.82 | SLC2A1 (0.53) | SLC2A1KCNH2KDM4E | |
| SCHEMBL5754720 | 0.81 | SLC2A1 (0.59) | SLC2A1KCNH2KDM4E | |
| SCHEMBL5754726 | 0.81 | SLC2A1 (0.59) | SLC2A1KCNH2KDM4E | |
| SCHEMBL4273379 | 0.79 | SLC2A1 (0.59) | SLC2A1KCNH2KDM4E | |
| SCHEMBL4273361 | 0.79 | SLC2A1 (0.59) | SLC2A1KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1719770-A2 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| EP-1320529-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-05-24 | — | — | EP | disclosed |
| US-20040053928-A1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-18 | — | — | US | disclosed |
| EP-1320529-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002024684-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053928-A1 | Quinoline derivatives as antibacterials | AAAS, QDPR, QARS1 | SLC2A1 3990/4885KCNH2 1839/4885SLC22A12 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.